Introduction of everolimus in kidney transplant recipients at a late posttransplant stage

This minireview focuses on the current knowledge about the introduction of everolimus (EVL), a mammalian target of rapamycin inhibitor, with calcineurin inhibitor (CNI) elimination or minimization in kidney transplant recipients at a late posttransplant stage. Within, we have summarized two major cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Uchida, Junji, Iwai, Tomoaki, Nakatani, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134274/
https://www.ncbi.nlm.nih.gov/pubmed/30211023
http://dx.doi.org/10.5500/wjt.v8.i5.150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134274/
https://www.ncbi.nlm.nih.gov/pubmed/30211023
http://dx.doi.org/10.5500/wjt.v8.i5.150

Ejemplares similares